Kevin Joseph Fitzgerald sold $531k of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 2,103 shares at an average of $252.71, traded Feb 14, 2025, filed Feb 18, 2025.
Score components
- +15RoleOfficer
- +18Trade size$531k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2025 | AGrant or award Common Stock10b5-1 | +2,103 | $0.00 | $0 | 14,984 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -145 | $252.50 | $37k | 14,839 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -164 | $253.37 | $42k | 14,675 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -110 | $254.35 | $28k | 14,565 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -47 | $255.56 | $12k | 14,518 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -53 | $256.29 | $14k | 14,465 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -26 | $257.51 | $6,695 | 14,439 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -33 | $258.07 | $8,516 | 14,406 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -12 | $259.72 | $3,117 | 14,394 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -21 | $260.57 | $5,472 | 14,373 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -26 | $261.45 | $6,798 | 14,347 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -12 | $263.33 | $3,160 | 14,335 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -14 | $264.87 | $3,708 | 14,321 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -1,086 | $250.21 | $272k | 13,235 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -115 | $251.60 | $29k | 13,120 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -80 | $256.05 | $20k | 13,040 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -76 | $257.79 | $20k | 12,964 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -83 | $259.10 | $22k | 12,881 | Feb 18, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 35Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $16M 50,937 shares | -63% | |
| 15Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $3.1M 11,250 shares | -40% | |
| 23Weak | ALNYbuy ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $10k 36 shares | - | |
| 45Moderate | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8,383 36 shares | -100% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $2.2M 7,440 shares | -98% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $2.9M 9,766 shares | -40% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $945k 3,877 shares | -4% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $308k 1,264 shares | -3% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $621k 2,557 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.